Table 2.
Gliclazide pharmacokinetic parameters in Caucasian and Aboriginal subjects derived from noncompartmental analysis. Data are mean ± s.d.
| Caucasian | Aboriginal | 95% CI on difference | |
|---|---|---|---|
| Baseline serum concentration (mg l−1) | 5.7 ± 4.7 | 3.4 ± 3.0 | 1.5, −6.1 |
| Area under the curve (AUC(0,∞) (mg l−1 h) | 171.1 ± 59.9 | 143.3 ± 84.7 | 44.0, −99.6 |
| Maximum serum concentration (Cmax; mg l−1) | 15.0 ± 3.7 | 14.1 ± 5.1 | 3.5, −5.2 |
| Time to maximum concentration (tmax; h) | 2.8 ± 1.6 | 2.1 ± 0.7 | 0.5, −1.8 |
| Volume (l kg−1) | 0.23 ± 0.11 | 0.29 ± 0.15 | 0.19, −0.07 |
| Mean residence time (h) | 18.8 ± 4.3 | 18.8 ± 4.1 | 4.1, −4.1 |
| Elimination half-time (t½,z; h) | 12.5 ± 2.3 | 14.2 ± 4.1 | 5.1, −1.6 |
| Systemic clearance (CL/F; l h−1 kg−1) | 0.012 ± 0.006 | 0.015 ± 0.008 | 0.010, −0.003 |
| Free gliclazide in serum (%) | 4.7 ± 0.8 | 4.6 ± 1.2 | 1.0, −1.1 |